Survey: Gastroenterologists Will Prescribe Biosimilars, But Have Concerns

As FDA considers an application for a biosimilar to treat Crohn's Disease, a survey of gastroenterologists shows that most are willing to prescribe biosimilars despite some concerns, such as FDA's use of extrapolation for indications. Some also would only want substitution of a biosimilar if a doctor is notified by a pharmacist that the switch has taken place. FDA approved the first U.S. biosimilar in March, and is currently reviewing Celltrion, Inc.'s application for an infliximab biosimilar of Janssen Biotech...